syncromune™ is a clinical stage biopharmaceutical company focused on the development of a new generation of personalized medicine for metastatic cancers. We uniquely specialize in optimizing intratumoral immunotherapy, and endeavor to be the world leader in this new class of immunotherapy. We are advancing the development of our promising syncrovax™ platform for several types of metastatic cancers.syncrovax™ is a novel platform technology that uses intratumoral sync technology™ (IST) to synchronize the timing and location of 3 critical components within the tumor microenvironment and draining lymph nodes: liberated tumor antigens, immune system components and our proprietary multi-molecule immunotherapeutic drug.We are developing this synchronization platform to enable the patient’s immune system to create a personalized therapeutic autologous vaccine that recognizes and attacks cancer throughout the body. The potential implications of using syncrovax™ to treat metastatic solid tumors are compelling and far-reaching and could meaningfully improve patient outcomes.

Founded by Eamonn Hobbs, Hobbs Medical Ventures is a consulting firm specializing in developing, delivering and implementing solutions for the medical device and combination medical device/pharmaceutical industries.Mr. Hobbs is an entrepreneurial senior executive with over 30 years of demonstrated success in profitable medical device business creation, strategy, general management, sales and marketing, and product development.He is a high-integrity, passionate leader known for exceptional abilities in developing strong customer/physician relationships and building top-performing sales and operational teams. Areas of excellence include: • Strategy• Product Innovation & Development • Successful Product Commercialization • Financial Planning and Operational Performance • Building Strong Sales Teams • Influencing Government Policy • Optimizing Business Processes• Mergers and Acquisitions• Operational Integrations• Fund Raising

The mission of the Translational Accelerator is to provide scientists the necessary tools, training, and resources to facilitate and accelerate the translation of inventions with potential commercial value from bench to bedside. Involved in the advising, training and mentoring of physician scientist inventors affiliated with the Brigham and Women’s Hospital and Harvard Medical School.  Assist the scientists in advancing their inventions and efficiently increasing their commercial value.

Partner and Member of the Senior Executive Advisory Team, providing commercialization and growth consulting to biotech and medtech companies.

Member, Audit and Compensation CommitteesOraSure Technologies, NASDAQ: OSUR, is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.For more information on OraSure Technologies, please visit www.orasure.com.

Marvao has developed a potentially game changing platform technology that seeks to dramatically reduce catheter infections by revolutionizing how tunneled catheters are placed and maintained. In initial clinical data comprised of thousands of catheter days, the NexSite tunneling system has demonstrated a zero catheter related blood infection rate, (CRBI) and even more remarkable, NexSite has done this in some of the most challenging applications such as femoral dialysis catheters (which normally have a very high 5-7% CRBI rate). CRBI has risen to be one of the highest profile issues with hospital administrators since it is life threatening, treatment costs are very high but not reimbursed, and reducing the hospital CRBI rate recently became one of the top quality measures that determine each hospital’s across the board reimbursement rate for all of the hospital’s procedures under the new accountable care system. With this in mind, hospital administrators as well as clinicians have placed a very high priority on embracing any new technologies that materially reduce the CRBI rate. The NexSite system can be mated with any tunneled catheter system so it has broad market utility including applications in dialysis and central lines. NexSite Dialysis Catheters very recently received FDA clearance and CE Mark is pending.

Member of the Audit, Governance and Compensation Committees.Harmonic Medical is a Toronto based development stage company involved in the development of proprietary ultrasound guided high intensity focused ultrasound (HIFU) therapy systems.

The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, D.C. that represents independent manufacturers of medical devices, diagnostic products and health care information systems. MDMA seeks to improve the quality of patient care by influencing government policy, encouraging the development of new medical technology, and fostering the availability of beneficial innovative products.Member, Executive, Governance, Membership and Compensation Committees

ImmunSYS is an immunotherapeutic drug and device company focused on the development of a new late stage metastatic prostate cancer therapy called MyVaccx™. MyVaccx™ empowers the patient’s own immune system to fight off cancer. It achieves this via a focal treatment of the solid tumor via a proprietary antigen presentation medical device system, immediately followed by the intra-tumoral injection of a proprietary depot drug formulation that contains a combination of immunotherapeutics and immunostimulants. The immune system then immediately creates an autologous vaccine that attacks the cancer throughout the body. The MyVaccx™ Phase I data is compelling in that the therapy has delivered a 35% complete response rate in late stage metastatic prostate cancer patients. The complete responses have been durable in that the longest patient was treated almost 3 years ago and is still disease free. These results are even more impressive considering that prostate cancers have not responded to any of the numerous systemically administered immunotherapy studies completed to date. The Phase I study included some additional adenocarcinomas which also produced a very positive signal; therefore, we believe the technology is potentially a broad platform and a new “Operating System” for immunotherapy.

IlluminOss Medical has developed a platform, disruptive technology for the orthopedic trauma market. It has achieved CE Mark approval in Europe, and has filed for expanded indications there. IlluminOss has also completed its US pivotal clinical trial and is pursuing FDA approval via a De Novo 510(k) that is currently under review. The technology centers around image guided, minimally invasive conforming orthopedic implants that leverage it’s proprietary bone stabilization technology, the "IlluminOss System". Through the unique and proprietary combination of balloons, light activated monomers and flexible catheters, IlluminOss has created the world’s first patient conforming intramedullary implant. The IlluminOss System has been safely and effectively used internationally since 2010 for a wide variety of clinical indications.IlluminOss recieved FDA approval in late 2017 and is recruiting U.S distributors to represent the product.

DCT was founded in 2015 with the goal of bringing to market easy to administer and non-invasive tests to detect presymptomatic cognitive impairment. Based on over 10 years of research and development at Lahey Hospital & Medical Center and MIT, our patented technology is proven to deliver accurate and objective indicators of cognitive function and is poised to make a significant impact on the medical community. DCT develops tests that detect presymptomatic cognitive impairment and aid in tracking cognitive change. In under 2 minutes, the technology can identify subtle cognitive features that may be indicative of impairment, even in people who appear to be functioning normally. All DCT’s tests are designed to be non-invasive and easy to administer. The tests use patented technology to capture and analyze micro-movements of drawing behavior, which reflect memory and thinking processes. DCT’s proprietary analysis instantly delivers accurate and objective indicators of cognitive state, all for a fraction of the price of imaging and biomarker analysis.

Antares Pharma is a revenue-generating product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors. Antares operates in two locations with the corporate offices in Ewing, NJ, and the Parenteral Products Division in Minneapolis, MN.

Member Audit and Governance CommitteesAntares Pharma, Inc. (NASDAQ: ATRS) is committed to developing and commercializing novel combination (drug and device) products utilizing the company’s unique, advanced drug delivery systems. ATRS products are patient focused: they typically improve safety and efficacy, reduce side effects and enable delivery at a lower dose. Antares advanced drug delivery systems are also well positioned for “life cycle extension” options.

Morris Innovative has developed and is commercializing two vascular closure device systems called FISH, which stands for Femoral Inserted Sheath Hemostasis. FISH CombiClose is a very unique combination working sheath/closure sheath system. The FISH InstaClose was very recently introduced procedure ending exchange system that delivers greatly simplified use, and shorter clinician learning curve. Both systems have multiple unique features and benefits that highly differentiate them from the competition. Morris has sold over 30,000 systems in the US so far, and recently received CE Mark approval, so the technology is very well proven.

Glens Falls Hospital provides comprehensive health care services to Warren, Washington, northern Saratoga, Essex, Hamilton, and northern Rensselaer counties. Our 27 regional facilities include health centers in Cambridge, Corinth, Granville, Greenwich, Hoosick Falls, Salem, Whitehall, and Wilton.Member of the Strategic Planning Committee, Patient Safety and Quality Committee

Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as ChemoSaturation (CS) for Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is approved and is pursuing reimbursement in the EU and is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver.

Chairman of the Board (only independent member)Early commercial stage (EU), venture capital backed company with a unique solution to treating coronary artery side branch disease.

Member, Audit and Compensation Committees. Sentinelle Medical Inc., established in 2004, is a private company based in Toronto, Canada that provides a suite of very high performance MR coils, and software solutions for GE, Toshiba and Siemens, providing health care providers with a fully integrated breast imaging and treatment planning system that result in the highest quality of patient care. Company achieved profitability and positive cash flow in Q4 2008. Very successful exit for investors upon sale of company to Hologic.

Co-founded a very successful medical device company that designs, develops, manufactures and markets image guided, minimally invasive devices for the targeted treatment of cancer and vascular disease. Company went from green field start up to leadership market share with premium positioning in core products against much larger, heavily entrenched competition.

Founding member of charitable scientific research and education foundation established in collaboration with its parent medical specialty society, American College of Phlebology, for the purpose of advancing the treatment of venous disease through research and education. Assisted in the creation of the society’s first Strategic Plan.Numerous committee memberships

SIRF is a charitable scientific research and education foundation established in collaboration with its parent medical specialty society, Society of Interventional Radiology, for the purpose of advancing interventional radiology through research and education. Sole Industry member of the Board; numerous committee positions held throughout tenure.

E-Z-EM, Inc. (NASDAQ: EZEM; Now Bracco Diagnostics, USA) is the world leader in GI contrast media and delivery systems, with associated businesses in vascular contrast and delivery systems.

Medical Device Company focused on serving the needs of Interventional Cardiologists. Attained worldwide market leadership in Angiographic Manifolds and Control Syringes. Sold to Pfizer in 1992, later sold to Boston Scientific in 1997, and AngioDynamics in 2012.

Secured venture capital funding, founded and developed a profitable medical device firm focusing on trans-endoscopic interventional devices for Gastroenterologists. Sold company in 1985; remains in operation today as a private company: www.hobbsmedical.com.